野生型转甲状腺素蛋白淀粉样变性心肌病中[123I]-MIBG SPECT/CT绝对定量与左心室分割的可行性:I-NERVE研究
单中心描述性横断面研究纳入29例ATTRwt-CM患者,采用[123I]-MIBG SPECT/CT进行左心室整体及节段绝对示踪剂摄取定量(kBq/mL、SUV、%ID)。所有患者均存在心脏交感神经元功能障碍,SUVmean、SUVpeak、SUVmax和%ID与半定量[123I]-MIBG指标相关,但与超声GLSS及CMR原生T1、ECV无相关性。
要点
- ATTRwt-CM患者[123I]-MIBG SPECT/CT左心室容积定量可行。
- SUVmean、SUVpeak、SUVmax、%ID与半定量[123I]-MIBG指标相关。
- 上述定量指标与超声GLSS及CMR原生T1、ECV无相关性。
核心结论
- 本研究证明[123I]-MIBG SPECT/CT在ATTRwt-CM中实现容积定量的可行性。
- SUVmean、SUVpeak、SUVmax和%ID与半定量指标相关,但与超声和CMR关键心脏参数不相关。
- 这证实[123I]-MIBG SPECT/CT对心脏功能或病理不同方面的敏感性。
研究设计与样本
- 单中心、描述性、横断面研究,前瞻性纳入29例ATTRwt-CM患者(75.8 ± 6.6岁,90%男性)。
- 采用[123I]-MIBG SPECT/CT定量左心室整体及节段绝对示踪剂摄取,以kBq/mL、SUV和%ID表示。
- 超声心动图、CMR和骨显像按临床标准进行,节段[123I]-MIBG SPECT/CT值与超声GLSS及CMR原生T1、ECV(SPECT/CT融合CMR)进行相关性分析。
- 试验注册:EudraCT ref. 2020-003350-72,于2023年3月20日回顾性注册;NCT05776212。
主要发现
- 所有患者均存在心脏交感神经元功能障碍,晚期心纵隔比中位数1.69(1.45-1.89),洗脱率22.7%(16.4%-27.3%)。
- SUVmean为1.80 ± .78,SUVpeak为3.84 ± 1.41,SUVmax为4.46 ± 1.68,%ID为.46 ± .18。
- SUVmean、SUVpeak、SUVmax和%ID与半定量[123I]-MIBG指标相关。
- 未发现与超声GLSS或CMR原生T1和ECV的相关性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiac sympathetic neuronal dysfunction is an early marker in wild-type transthyretin amyloidosis cardiomyopathy (ATTRwt-CM). Iodine-123-labeled norepinephrine analog meta-iodobenzylguanidine ([123I]-MIBG) imaging evaluates cardiac sympathetic innervation but lacks volumetric activity quantification in current methods. This study aims to quantify cardiac sympathetic neuronal dysfunction in ATTRwt-CM using [123I]-MIBG single-photon emission computed tomography/ computed tomography (SPECT/CT) and correlate findings with functional and structural cardiac parameters from echocardiogram and cardiac magnetic resonance imaging (CMR). METHODS: We conducted a single-center, descriptive, cross-sectional study to quantify absolute myocardial sympathetic function in ATTRwt-CM using [123I]-MIBG SPECT/CT. Retrospective reconstruction allowed for absolute tracer-uptake quantification of the left ventricle, overall and segmented, in kBq/mL, standard uptake value (SUV), and percentage of the injected dose (%ID). Echocardiography, CMR, and bone scintigraphy were performed according to clinical standards. Segmented [123I]-MIBG SPECT/CT values were correlated with global longitudinal systolic strain (GLSS) on echocardiography, native-T1, and extracellular volume (ECV) on CMR using SPECT/CT fused with CMR. RESULTS: Twenty-nine ATTRwt-CM patients (75.8 ± 6.6 years, 90% male) were prospectively included. All exhibited cardiac sympathetic neuronal dysfunction, with a median late heart-to-mediastinum ratio of 1.69 (1.45-1.89) and a washout rate of 22.7% (16.4%-27.3%). SUVmean, SUVpeak, SUVmax, and %ID were 1.80 ± .78, 3.84 ± 1.41, 4.46 ± 1.68, and .46 ± .18, respectively, correlating with semiquantitative [123I]-MIBG measures. No correlations were found with GLSS on echocardiography or native T1 and ECV on CMR. CONCLUSIONS: The current study demonstrates the feasibility of volumetric quantification of [123I]-MIBG SPECT/CT in ATTRwt-CM. SUVmean, SUVpeak, SUVmax, and %ID correlate with semi-quantitative measures but not with key cardiac parameters on echocardiography or CMR. This confirms the sensitivity of [123I]-MIBG SPECT/CT to different aspects of cardiac function or pathology. TRIAL REGISTRATION: EudraCT ref. 2020-003350-72, retrospectively registered March 20, 2023. https://classic. CLINICALTRIALS: gov/ct2/show/NCT05776212.
引用
- Tubben A, Prakken NHJ, Ivashchenko OV, et al. Feasibility of the absolute quantification and left ventricular segmentation of cardiac sympathetic innervation in wild-type transthyretin amyloidosis cardiomyopathy with [123I]-MIBG SPECT/CT: The I-NERVE study. J Nucl Cardiol. 2025. PMID: 39909199. doi:10.1016/j.nuclcard.2025.102146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。